In a landmark decision announced on September 6, 2022 (“Decision”), the European Commission (“EC”) prohibited the acquisition by Illumina, a U.S. company specialising in genomic sequencing, of GRAIL, a U.S.- based start-up developing early cancer-detection tests (“Transaction”).  The EC blocked the Transaction even though it did not meet notification thresholds under the EU Merger Regulation (“EUMR”) or in any Member State: at the time of prohibition, GRAIL had not launched a product on the market and had no sales in the EEA. This is the first time the EC has reviewed – and blocked – a transaction falling below the EUMR and referring Member State notification thresholds.  Factual Background Illumina’s principal business is next-generation sequencing (“NGS”) instruments and consumables.
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.